Inovio shares down on missed Q2 projections as it moves forward with COVID-19 vaccine

By Sean Whooley | August 10, 2021

inovio Inovio Pharmaceuticals (NSDQ:INO) shares took a hit this morning on second-quarter results that missed the consensus forecast.

INO shares were down more than –11% at $8.53 per share in morning trading today.

Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: Inovio Pharmaceuticals

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].